Vivos Inc CEO purchases $5,880 worth of company stock

In a recent transaction on August 7, 2024, Michael K. Korenko, the CEO and President of Vivos Inc (OTCMKTS:RDGL), a company specializing in surgical and medical instruments, has purchased 50,000 shares of common stock at a price of $0.1176 per share, amounting to a total investment of $5,880.

This purchase has increased Korenko's total holdings in the company to 10,285,090 shares of common stock. The transaction was reported in a Form 4 document filed with the Securities and Exchange Commission (SEC). The acquisition of these shares demonstrates a continued commitment by the company's leadership to its future growth and stability.

Investors often monitor insider transactions as they can provide insights into the executive's view of the company's valuation and potential. The actions of executives such as buying or selling shares in their own companies can sometimes be considered a signal of their confidence in the company's prospects.

Vivos Inc, formerly known as Advanced Medical Isotope Corp, is incorporated in Delaware and has its business operations based in Richland, Washington. The company's stock is traded on the OTCMKTS under the trading symbol RDGL.

The details of the transaction, including the number of shares purchased and the price paid per share, are publicly available in the Form 4 filing with the SEC. This filing is a requirement for officers, directors, and significant shareholders in public companies, which must be submitted within two business days following the transaction date.

For further information about Vivos Inc and its recent insider transactions, investors can refer to the company's filings with the SEC.

InvestingPro Insights

Following the recent insider transaction by Vivos Inc's CEO, Michael K. Korenko, market participants are showing keen interest in the company's financial health and future prospects. According to InvestingPro data, Vivos Inc (OTCMKTS:RDGL) currently has a market capitalization of $49.65 million. Despite a significant return over the last week with a 30.09% price total return, the company's stock has experienced volatility over various timeframes, with a 41.04% decline in the last month and a substantial 110.38% increase over the last six months.

An InvestingPro Tip highlights that analysts are anticipating a sales decline in the current year, which aligns with the reported revenue decline of 38.98% from the last twelve months as of Q1 2024. This could be a factor for investors to consider when assessing the company's growth trajectory. Additionally, a critical metric for potential investors is the company's gross profit margin, which has been weak at -33.33% for the same period. This indicates challenges in maintaining profitability which could be a concern for stakeholders.

Despite these challenges, an important InvestingPro Tip to note is that Vivos Inc is a niche player in the surgical and medical instruments industry, which could offer unique market opportunities. The company's liquid assets also exceed short-term obligations, suggesting a degree of financial flexibility in the near term.

For those interested in a deeper analysis of Vivos Inc, InvestingPro offers additional tips on the company's financials and performance. There are 11 more InvestingPro Tips available that provide insights into the company's valuation, profitability, and industry positioning, which can be accessed for a comprehensive investment evaluation.

With the next earnings date slated for August 8, 2024, investors and analysts will be watching closely to see if the company's strategic initiatives align with financial improvements in the upcoming quarter.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.